| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TNYA | Common Stock | Award | $0 | +107,500 | +57% | $0.000000 | 295,831 | 06 Feb 2025 | Direct | F1, F2, F3 |
| transaction | TNYA | Common Stock | Award | $0 | +34,424 | +12% | $0.000000 | 330,255 | 06 Feb 2025 | Direct | F1, F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TNYA | Stock Option (Right to buy) | Award | $0 | +650,000 | $0.000000 | 650,000 | 06 Feb 2025 | Common Stock | 650,000 | $1.00 | Direct | F6 | |
| transaction | TNYA | Stock Option (Right to Buy) | Disposed to Issuer | -353,271 | -100% | 0 | 06 Feb 2025 | Common Stock | 353,271 | $5.64 | Direct | F7, F8, F9 | ||
| transaction | TNYA | Stock Option (Right to Buy) | Award | +353,271 | 353,271 | 06 Feb 2025 | Common Stock | 353,271 | $1.21 | Direct | F7, F8, F9 | |||
| transaction | TNYA | Stock Option (Right to Buy) | Disposed to Issuer | -161,214 | -100% | 0 | 06 Feb 2025 | Common Stock | 161,214 | $9.36 | Direct | F8, F9, F10 | ||
| transaction | TNYA | Stock Option (Right to Buy) | Award | +161,214 | 161,214 | 06 Feb 2025 | Common Stock | 161,214 | $1.21 | Direct | F8, F9, F10 | |||
| transaction | TNYA | Stock Option (Right to Buy) | Disposed to Issuer | -401,390 | -100% | 0 | 06 Feb 2025 | Common Stock | 401,390 | $15.19 | Direct | F8, F9, F11 | ||
| transaction | TNYA | Stock Option (Right to Buy) | Award | +401,390 | 401,390 | 06 Feb 2025 | Common Stock | 401,390 | $1.21 | Direct | F8, F9, F11 |
| Id | Content |
|---|---|
| F1 | Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. |
| F2 | The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2025, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. |
| F3 | Includes 260,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| F4 | The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the total number of shares subject to the restricted stock unit award on May 15, 2025, and 1/4th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. |
| F5 | Includes 294,424 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| F6 | Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. |
| F7 | The shares underlying the option are fully vested and exercisable. |
| F8 | The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. |
| F9 | Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. |
| F10 | 1/48th of the shares underying the option vested on July 17, 2021, and the remaining shares vest in 48 equal monthly installments thereafter. |
| F11 | 1/48th of the shares underying the option vested on March 15, 2022, and the remaining shares vest in 48 equal monthly installments thereafter. |